Advanced Recomp (GH secretagogue + repair)
Why this combination
This is a body-recomposition construction that combines two goals in one protocol: amplifying the body's own growth-hormone output and supporting tissue recovery. The GH side uses the classic secretagogue pairing — CJC-1295 (no-DAC), a GHRH analog that increases the amount of GH released per pulse, plus ipamorelin, a selective ghrelin-receptor agonist that triggers a clean GH pulse without raising cortisol or prolactin. Acting on two different receptors, they amplify pulsatile GH and downstream IGF-1 more than either does alone.
BPC-157 is added for the recovery side. It is a stable gastric pentapeptide associated in preclinical work with angiogenesis and tendon, ligament, muscle, and gut healing. The rationale is that during an aggressive training block aimed at simultaneously building muscle and losing fat, the GH secretagogues support the anabolic/lipolytic environment while BPC-157 helps tissues tolerate and recover from the higher training volume.
This is a community concept with no controlled trials of the combination — the GH-secretagogue evidence is largely endocrine/pharmacologic and the BPC-157 evidence is preclinical and anecdotal. It is presented at community confidence; the appeal is convenience and mechanism-stacking rather than proven recomposition outcomes.
Per-compound dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| CJC-1295 no-DAC | 100 mcg | 1–3× daily | Often dosed before bed on an empty stomach to amplify the natural overnight GH pulse. |
| Ipamorelin | 100 mcg | 1–3× daily | Commonly matched 1:1 with CJC-1295 no-DAC so the two can share a vial. |
| BPC-157 | 250–500 mcg | 1–2× daily | Often split AM/PM; community-derived range. |
Reconstitution math
For educational and research reference only. Not intended for human consumption, not medical advice. Compounds discussed are sold and used for laboratory research purposes only.
Separate vials
CJC-1295 no-DAC — reconstitute a 5 mg vial with 3 mL bacteriostatic water → 1,666.7 mcg/mL; a 100 mcg dose is 0.06 mL (6 units). Using 3 mL keeps the small dose above the hard-to-measure 5-unit mark.
Ipamorelin — 5 mg + 3 mL → 1,666.7 mcg/mL; 100 mcg = 0.06 mL (6 units), identical to CJC-1295 no-DAC.
BPC-157 — 5 mg + 2 mL → 2,500 mcg/mL; 250 mcg = 0.1 mL (10 units) and 500 mcg = 0.2 mL (20 units).
Pre-blended (single vial)
Blend only the two GH secretagogues. Combine CJC-1295 no-DAC 5 mg + ipamorelin 5 mg in one vial and add 3 mL → each is 1,666.7 mcg/mL, so a single 0.06 mL draw (6 units) delivers 100 mcg of each in one injection.
Keep BPC-157 in its own vial. Its dose is larger and it is often run on a different schedule (including longer continuous use for an injury), so a fixed three-way blend would sacrifice that flexibility for little gain.
Verify any blend with the reconstitution calculator before dosing — concentrations change for every compound when you alter the water volume.
Cycle length & alternatives
- Cycle length
- Typically an 8–12 week recomposition block, frequently dosed 5 days on / 2 days off for the GH secretagogues; BPC-157 is sometimes continued as needed for active recovery.
- Compared to alternatives
- Versus CJC-1295 + ipamorelin alone, this adds BPC-157's recovery angle, bridging the GH-optimization and tissue-repair categories. Versus the Wolverine repair stack (BPC-157 + TB-500), it trades the second repair peptide for a GH-axis pair, shifting the emphasis from pure healing toward recomposition. More moving parts than any single-goal stack, and the combined effect is anecdotal rather than trial-backed.
Sources & references
Frequently asked questions
Who is this stack aimed at?
It is a community 'recomposition' concept for people running a demanding training block who want GH-axis support and tissue recovery at the same time. There are no controlled trials of the three together, so it carries community confidence.
Why blend only two of the three compounds?
CJC-1295 no-DAC and ipamorelin are both dosed at 100 mcg, so they blend cleanly into one 6-unit injection. BPC-157 uses a larger dose and is often run on its own schedule, so keeping it separate preserves flexibility.
Does this build muscle and burn fat at once?
That is the intent behind 'recomposition,' but it is a mechanistic rationale, not a proven outcome — the GH-secretagogue data are pharmacologic and the BPC-157 data are preclinical/anecdotal. Diet and training remain the primary drivers.
For educational and research reference only. Not intended for human consumption, not medical advice. Compounds discussed are sold and used for laboratory research purposes only.
Related stacks
CJC-1295 (no-DAC) + Ipamorelin
This is the classic growth-hormone-secretagogue pairing. CJC-1295 without DAC (a GHRH analog, also called Mod GRF 1-29) increases the amount of GH released per pulse, while Ipamorelin (a selective ghrelin-receptor agonist) triggers a clean GH pulse with minimal effect on cortisol or prolactin.
Wolverine (BPC-157 + TB-500)
The 'Wolverine' stack pairs two of the most widely discussed repair peptides because their proposed mechanisms are complementary rather than redundant. BPC-157 is associated with angiogenesis and localized tendon/ligament/gut signaling, while TB-500 (a synthetic fragment of thymosin beta-4) is associated with actin regulation and cell migration across tissue.
Tesamorelin + Ipamorelin
This pairing follows the classic GH-secretagogue logic of combining a GHRH analog with a ghrelin-receptor (GHRP) agonist, but upgrades the GHRH side to tesamorelin — a stabilized GHRH analog that is the only growth-hormone-axis peptide in this category with FDA-approved human efficacy data, specifically for reducing visceral adipose tissue in HIV-associated lipodystrophy (marketed as Egrifta). The premise is that tesamorelin amplifies the size of each GH pulse at the pituitary while ipamorelin, a highly selective ghrelin-receptor agonist, both adds a second, independent pulse trigger and suppresses somatostatin, the brake on GH release.